TABLE 2.
MICs and β-lactamases found in 10 non-ertapenem-susceptible isolates from IAIs in the United States in 2009 to 2013
| Year | State | Patient age (yr) | Typea | MIC (μg/ml)b |
Molecular characteristicsc |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ETP | IPM | FEP | CTX | CAZ | FOX | TZP | CIP | AMK | OSBL | ESBL | AmpC | Carbapenemase | ||||
| 2009 | Ohio | 61 | HA | >4 | 8 | 8 | 128 | 128 | >16 | 64 | ≤0.25 | ≤4 | CMY-2 | |||
| 2010 | California | 2 | CA | >4 | >8 | 8 | 128 | >128 | >16 | >64 | 0.5 | ≤4 | TEM | CMY-2 | ||
| 2010 | California | 46 | NA | 1 | 0.25 | >32 | >128 | >128 | >16 | >64 | >2 | 32 | CTX-M-15 | |||
| 2010 | Pennsylvania | 49 | HA | >4 | >8 | >32 | >128 | >128 | >16 | >64 | >2 | ≤4 | SHV-12 | KPC-2 | ||
| 2011 | Pennsylvania | 51 | CA | >4 | 8 | >32 | >128 | 128 | >16 | >64 | >2 | ≤4 | SHV-12 | KPC-2 | ||
| 2011 | New York | 56 | CA | >4 | 4 | >32 | >128 | >128 | >16 | >64 | >2 | >32 | TEM | SHV-5 | KPC-3 | |
| 2012 | California | 55 | HA | 2 | 0.25 | 4 | ≤0.5 | ≤0.5 | 16 | 64 | >2 | 16 | TEM | |||
| 2012 | Georgia | 86 | CA | >4 | 8 | 8 | 32 | 128 | >16 | 64 | >2 | ≤4 | TEM | CMY-2 | ||
| 2013 | Michigan | 67 | HA | 2 | 0.25 | 32 | 32 | 16 | 16 | 32 | >2 | 16 | CTX-M-71 | |||
| 2013 | New York | 80 | HA | >4 | 4 | >32 | >128 | 128 | >16 | >64 | >2 | ≤4 | TEM | KPC-3 | ||
a
HA, hospital-associated (hospital stay of ≥48 h at the time of specimen collection); CA, community-associated (hospital stay of <48 h); NA, not available.
b
ETP, ertapenem; IPM, imipenem; FEP, cefepime; CTX, cefotaxime; CAZ, ceftazidime; FOX, cefoxitin; TZP, piperacillin-tazobactam; CIP, ciprofloxacin; AMK, amikacin.
c
OSBL, original-spectrum β-lactamase; ESBL, extended-spectrum β-lactamase; AmpC, plasmid-encoded class C β-lactamase.